Drug intelligence / Profile preview

IGT-302

Development stage: Preclinical
Lead developer: Ingenia Therapeutics
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics

Overview

IGT-302 is a monoclonal antibody drug candidate developed by Ingenia Therapeutics. It is being investigated for the treatment of glaucoma, an eye disease characterized by increased intraocular pressure that can lead to vision loss. The drug is currently in preclinical development and has not yet entered clinical trials or received regulatory approval. Its precise mechanism of action and molecular targets have not been publicly disclosed as of June 2025[1][2][3][4].

Beyond the preview

Go deeper on IGT-302.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on IGT-302.

Explore the full profile